...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.
【24h】

A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.

机译:一种用于筛选异柠檬酸脱氢酶1(IDH1)突变的单管敏感多重方法。

获取原文
获取原文并翻译 | 示例

摘要

In the 8 April 2010 issue of Blood, we reported characterization of IDH1 mutation in a large cohort of acute myeloid leukemia (AML) patients. Very recently, a series of reports about this mutation in AML have been published in a cluster of manuscripts. As IDH1 mutation brings prognostic information in glioma and possibly AML, identification of IDH1 R132 mutations will bring increasing clinical relevance. Moreover, the mutation seems quite stable and may serve as a marker for monitoring minimal residual disease. Hence, a sensitive and simple method for detecting this mutation will be highly desirable. We here report a very sensitive, single-tube, multiplex polymerase chain reaction (PCR)-based method, which has been verified by direct sequencing method. With this method, we then determined the stability of the R132 mutation in sequential samples of AML and measured the incidence of this mutation in a cohort of patients with myelodysplastic syndrome (MDS). This study has been approved by the Institutional Review Board of the National Taiwan University Hospital.
机译:在2010年4月8日的《血液》杂志中,我们报道了一大批急性髓细胞性白血病(AML)患者的IDH1突变特征。最近,一系列关于AML中这种突变的报告已发表在一系列手稿中。由于IDH1突变可带来神经胶质瘤和AML的预后信息,因此IDH1 R132突变的鉴定将带来越来越高的临床相关性。而且,该突变似乎很稳定,可以作为监测最小残留疾病的标志。因此,非常需要一种灵敏且简单的检测该突变的方法。我们在这里报告了一种非常灵敏的单管多重聚合酶链反应(PCR)为基础的方法,该方法已通过直接测序方法进行了验证。然后,使用这种方法,我们确定了AML连续样本中R132突变的稳定性,并测量了该组在骨髓增生异常综合征(MDS)患者中该突变的发生率。该研究已获得台湾大学医院机构审查委员会的批准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号